Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis Idylla Liquid Biopsy and Colorectal Cancer Assays

Biocartis has launched two new research-use-only products for its Idylla molecular diagnostics platform. The first product, the Idylla ctBRAF Mutation Assay, uses blood plasma as a sample, and according to the company is the first fully automated liquid biopsy assay that can potentially act as a substitute for tissue biopsy testing in melanoma, colorectal, and lung cancers, as well as conditions such as hairy cell leukemia and histiocytosis. The assay has a turnaround time of approximately 90 minutes with less than one minute of hands-on time.

The second product, the Idylla NRAS-BRAF-EGFR S492R Mutation Assay complements the already CE-marked Idylla KRAS Mutation Test. Together, these provide complete metastatic colorectal cancer mutation analysis using two slices of formalin-fixed, paraffin-embedded tumor tissue.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.